期刊
CLINICAL INFECTIOUS DISEASES
卷 52, 期 -, 页码 S346-S350出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir050
关键词
-
资金
- Food and Drug Administration
- Infectious Diseases Society of America
- AstraZeneca Pharmaceuticals
- Bio Merieux, Inc.
- Cepheid
- Gilead Sciences
- Intelligent MDX, Inc.
- Inverness Medical Innovations
- Roche Molecular Systems
Serum procalcitonin (PCT) levels rapidly increase in patients with invasive bacterial disease. PCT levels increase faster than do C-reactive protein levels. Furthermore, a rapid decrease in the PCT level is supporting evidence that the source of the bacterial infection is responding to clinical management. In patients with community-acquired bacterial pneumonia, sequential PCT levels are useful as a guide to shorter courses of antimicrobial therapy. With use of emerging multiplex real-time polymerase chain reaction platforms for the detection of viral and bacterial respiratory pathogens, it should be possible to critically assess whether an elevated serum PCT level is a valid biomarker of invasive bacterial infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据